Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note released on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ BLPH opened at $0.06 on Monday. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $11.15. The company has a 50-day moving average of $0.05 and a two-hundred day moving average of $0.06. The company has a market cap of $672,650.00, a PE ratio of -0.07 and a beta of 0.67.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.